115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)
  7. Center for Hematologic Malignancies (13261)
  8. Hematologic Malignancies, Division of (13086)
  9. Sloan Kettering Institute Postdocs (12935)
  10. Department of Pathology and Laboratory Medicine (12608)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39031)
  2. GSK Faculty (22466)
  3. Solid Tumor Oncology Division (22055)
  4. Surgery (21246)
  5. Sloan Kettering Institute Faculty (16085)
  6. Survivorship Research (15761)

More Groups

People
  1. Marc Ladanyi (1326)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1049)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Promoting implementation of patient-reported outcomes in institutions caring for vulnerable and underserved cancer populations
    Meeting Abstract

    Schuster, A.; Crossnohere, N.; Vickers, A.; Vargo, M.; Smith, E.; Smith, C.; Sibbitt, B.; Shapiro, L.; Richardson, A.; Rainey, A. M.; more...
    Quality of Life Research (2024)

    Fulltext@MSK | Save
  • Global response score correlates with quality of life in cutaneous T-cell lymphoma
    Meeting Abstract

    Khan, N.; Drill, E.; Moskowitz, A.; Shinohara, M.; Larocca, C.; Querfeld, C.; Zain, J.; Horwitz, S.
    Quality of Life Research (2024)

    Fulltext@MSK | Save
  • Artificial intelligence in GPT-4 can interpret cancer patients' prognosis awareness without training: A zero-shot learning task
    Meeting Abstract

    Li, Y.; Petrov, A.; Aktinson, T. M.; Lynch, K. A.; George, L.; Kuperman, G.; Li, A.; Flory, J.; Stetson, P.
    Quality of Life Research (2024)

    Fulltext@MSK | Save
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Möhler, M.; Janjigian, Y.; Al-Batran, S. E.; Wainberg, Z.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L.; Oh, D. Y.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis
    Meeting Abstract

    Kümmel, S.; Jhaveri, K.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Randomized phase 3 study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaive, RET-mutant medullary thyroid cancer
    Meeting Abstract

    Hadoux, J.; Elisei, R.; Brose, M.; Hoff, A.; Robinson, B.; Gao, M.; Jarzab, B.; Isaev, P.; Kopeckova, K.; Wadsley, J.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
    Meeting Abstract

    Loong, H.; Goto, K.; Solomon, B.; Park, K.; Pérol, M.; Arriola, E.; Novello, S.; Cheng, Y.; Ardizzoni, A.; Mak, M.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) vs standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in high-risk subgroups
    Meeting Abstract

    Raab, M. S.; Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Cavo, M.; Callander, N.; Costa, L. J.; Moreau, P.; Solomon, S. R.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens in patients (pts) with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in the modified intent-to-treat (mITT) population
    Meeting Abstract

    Scheid, C.; Manier, S.; Ailawadhi, S.; Rodríguez-Otero, P.; Arnulf, B.; Patel, K.; Solomon, S. R.; Baz, R.; Jagannath, S.; Raje, N.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Borchmann, P.; Morschhauser, F.; Dahiya, S.; Palomba, M. L.; García-Sancho, A. M.; Ortega, J. L. R.; Kuruvilla, J.; Jäger, U.; Cartron, G.; Izutsu, K.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save